Caveolin Gene, a Possible Risk Factor for Metabolic Syndrome in Humans: A Systematic Review and Meta‑Analysis

Mohadeseh Arefian, Sadegh Mazaheri‑Tehrani, Maryam Yazdi, Roya Kelishadi

Abstract


Background: Studies show that caveolin genes are associated with metabolic disorders, so we aimed to systematically review the association between caveolin genes and metabolic syndrome in human studies. This systematic review is conducted based on the PRISMA 2020 checklist. Methods: A systematic literature search was done on electronic databases including Embase, Scopus, Medline (PubMed), and Web of Science until September 2023 and updated until June 2024. Human studies that were published in English were included without restricting other variables such as time, age, and gender. Results: At the first step, 10313 papers were found, and at the final step, nine studies were included in the systematic review, and four studies entered the quantitative analysis. The result showed that metabolic syndrome is significantly associated with minor alleles in the following genes: CAV‑1 rs1997623 (OR = 1.44 (95% CI: 1.2, 1.86)), CAV‑1 rs11773845, 22375–22375 del AC, and CAV‑1 rs3807992. No significant association was found for CAV‑1 rs926198 (OR = 1.61 (95% CI: 0.89‑2.92)), and 22285 C>T. Caveolin mRNA level was increased in the cases of metabolic syndrome. CAV‑1 rs1997623 A allele changes the transcription factor binding site to increase the attachment of EBF1. Conclusions: This results in the enhancement of promoter activity and further transcription of the caveolin‑1 gene. In conclusion, individuals carrying minor alleles for the CAV‑1 gene might have an increased risk for metabolic syndrome. With future studies focusing on the matter, this gene can be used as a screening tool for metabolic health to detect individuals with a higher genetic susceptibility to metabolic syndrome.

Keywords


CAV1; Caveolin; MetS; metabolic syndrome; obesity

Full Text:

PDF

References


Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci 2022;23:786.

Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, et al. Metabolic syndrome and associated diseases: From the bench to the clinic. Toxicol Sci 2018;162:36 42.

Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011 2016. JAMA 2020;323:2526 8.

Farmanfarma KK, Kaykhaei MA, Mohammadi M, Adineh HA, Ansari Moghaddam A. The prevalence and trend of metabolic syndrome in the South East of Iran. J Med Life 2020;13:587 99.

Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in mainland china: A meta analysis of published studies. BMC Public Health 2016;16:296.

Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic syndrome pathophysiology and predisposing factors. Int J Sports Med 2021;42:199 214.

de Souza GM, Borborema MED, de Lucena TMC, Santos AFD, de Lima BR, de Oliveira DC, et al. Caveolin 1 (CAV 1) up regulation in metabolic syndrome: All roads leading to the same end. Mol Biol Rep 2020;47:9245 50.

Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: An update on diagnostic criteria, pathogenesis, and genetic links. Hormones 2018;17:299 313.

Nwosu ZC, Ebert MP, Dooley S, Meyer C. Caveolin 1 in the regulation of cell metabolism: A cancer perspective. Mol Cancer 2016;15:71.

Chuengsamarn S, Garza AE, Krug AW, Romero JR, Adler GK, Williams GH, et al. Direct renin inhibition modulates insulin resistance in caveolin 1 deficient mice. Metabolism 2013;62:275 81.

Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, et al. A prevalent caveolin 1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. Metabolism 2015;64:1674 81.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640 5.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735 52.

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome A new world wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469 80.

Nizam R, Al Ozairi E, Goodson JM, Melhem M, Davidsson L, Alkhandari H, et al. Caveolin 1 variant is associated with the metabolic syndrome in Kuwaiti children. Front Genet 2018;9:689.

Al Madhoun A, Hebbar P, Nizam R, Haddad D, Melhem M, Abu Farha M, et al. Caveolin 1 rs1997623 variant and adult metabolic syndrome Assessing the association in three ethnic cohorts of Arabs, South Asians and South East Asians. Front Genet 2022;13:1034892.

Abaj F, Saeedy SAG, Mirzaei K. Mediation role of body fat distribution (FD) on the relationship between CAV1 rs3807992 polymorphism and metabolic syndrome in overweight and obese women. BMC Med Genomics 2021;14:202.

Al Madhoun A, Haddad D, Nizam R, Miranda L, Kochumon S, Thomas R, et al. Caveolin 1 rs1997623 single nucleotide polymorphism creates a new binding site for the early B cell factor 1 that instigates adipose tissue CAV1 protein overexpression. Cells 2022;11:3937.

Abaj F, Mirzaei K. Caveolin 1 genetic polymorphism interacts with PUFA to modulate metabolic syndrome risk. Br J Nutr 2022;127:1281 8.

Mora García G, Gómez Camargo D, Alario Á, Gómez Alegría C. A common variation in the caveolin 1 Gene Is associated with high serum triglycerides and metabolic syndrome in an Admixed Latin American population. Metab Syndr Relat Disord 2018;16:453 63.

Grilo A, Fernandez ML, Beltrán M, Ramirez Lorca R, González MA, Royo JL, et al. Genetic analysis of CAV1 gene in hypertension and metabolic syndrome. Thromb Haemost 2006;95:696 701.

Abou Ziki MD, Mani A. Metabolic syndrome: Genetic insights into disease pathogenesis. Curr Opin Lipidol 2016;27:162 71.

Haddad D, Al Madhoun A, Nizam R, Al Mulla F. Role of caveolin 1 in diabetes and its complications. Oxid Med Cell Longev 2020;2020:9761539.

Shastry BS. SNPs: Impact on gene function and phenotype. Methods Mol Biol 2009;578:3 22.

Griffin MJ, Zhou Y, Kang S, Zhang X, Mikkelsen TS, Rosen ED. Early B cell factor 1 (EBF1) is a key regulator of metabolic and inflammatory signaling pathways in mature adipocytes. J Biol Chem 2013;288:35925 39.

Gao H, Mejhert N, Fretz JA, Arner E, Lorente Cebrián S, Ehrlund A, et al. Early B cell factor 1 regulates adipocyte morphology and lipolysis in white adipose tissue. Cell Metab 2014;19:981 92.

Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: Their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes 2011;2011:490650.

Iggman D, Risérus U. Role of different dietary saturated fatty acids for cardiometabolic risk. Clin Lipidol 2011;6:209 23.